https://thepharmadata.com/rebuilding-trust-and-steering-bayer-towards-enhanced-performance/ 2024-04-27T05:58:51+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Rebuilding-Trust-and-Steering-Bayer-Towards-Enhanced-Performance.webp https://thepharmadata.com/modernas-showcase-of-respiratory-and-cytomegalovirus-research-at-the-escmid-global-congress/ 2024-04-27T05:50:29+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Modernas-Showcase-of-Respiratory-and-Cytomegalovirus-Research-at-the-ESCMID-Global-Congress.webp https://thepharmadata.com/chmp-grants-favorable-opinion-to-biogens-tofidence-tocilizumab-a-biosimilar-of-roactemra/ 2024-04-27T05:46:47+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/CHMP-Grants-Favorable-Opinion-to-Biogens-TOFIDENCE%E2%84%A2-tocilizumab-a-Biosimilar-of-ROACTEMRA.webp https://thepharmadata.com/chmp-recommends-fruquintinib-for-previously-treated-metastatic-colorectal-cancer/ 2024-04-27T05:42:02+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/CHMP-Recommends-Approval-of-Bristol-Myers-Squibbs-Opdivo%C2%AE-for-First-Line-Treatment-of-Unresectable-or-Metastatic-Urothelial-Carcinoma-1.webp https://thepharmadata.com/new-supervisory-board-elected-at-mercks-annual-general-meeting/ 2024-04-27T05:19:45+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Meeting.webp https://thepharmadata.com/european-commission-grants-approval-for-kalydeco-to-treat-cystic-fibrosis-in-infants-as-young-as-1-month-old-announces-vertex/ 2024-04-27T05:06:58+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/European-Commission-Grants-Approval-for-KALYDECO%C2%AE-to-Treat-Cystic-Fibrosis-in-Infants-as-Young-as-1-Month-Old-Announces-Vertex.webp https://thepharmadata.com/fda-grants-approval-to-pfizers-beqvez-a-single-dose-gene-therapy-for-hemophilia-b-in-adults/ 2024-04-27T04:58:33+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/FDA-Grants-Approval-to-Pfizers-BEQVEZ%E2%84%A2-A-Single-Dose-Gene-Therapy-for-Hemophilia-B-in-Adults.webp https://thepharmadata.com/amgen-prepares-to-present-marketing-authorization-application-for-teprotumumab-to-the-european-medicines-agency/ 2024-04-27T04:54:44+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Amgen-Prepares-to-Present-Marketing-Authorization-Application-for-Teprotumumab-to-the-European-Medicines-Agency.webp https://thepharmadata.com/ats-presentation-sanofis-innovations-in-immune-mediated-respiratory-therapies/ 2024-04-27T04:49:11+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/ATS-Presentation-Sanofis-Innovations-in-Immune-Mediated-Respiratory-Therapies.webp https://thepharmadata.com/chmp-recommends-approval-of-bristol-myers-squibbs-opdivo-for-first-line-treatment-of-unresectable-or-metastatic-urothelial-carcinoma/ 2024-04-27T04:42:40+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/CHMP-Recommends-Approval-of-Bristol-Myers-Squibbs-Opdivo%C2%AE-for-First-Line-Treatment-of-Unresectable-or-Metastatic-Urothelial-Carcinoma.webp https://thepharmadata.com/first-quarter-2024-financial-results-released-by-abbvie/ 2024-04-27T04:23:37+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/First-Quarter-2024-Financial-Results-Released-by-AbbVie.webp https://thepharmadata.com/neurocrine-biosciences-launches-ch-initiative-for-congenital-adrenal-hyperplasia-support/ 2024-04-25T04:58:59+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Neurocrine-Biosciences-Launches-C@H-Initiative-for-Congenital-Adrenal-Hyperplasia-Support.webp https://thepharmadata.com/bio-techne-initiates-patent-infringement-lawsuit-against-molecular-instruments/ 2024-04-25T04:52:09+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Bio-Techne-Initiates-Patent-Infringement-Lawsuit-Against-Molecular-Instruments.webp https://thepharmadata.com/moderna-teams-up-with-openai-to-propel-mrna-medicine-innovation/ 2024-04-25T04:43:03+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Moderna-Teams-Up-with-OpenAI-to-Propel-mRNA-Medicine-Innovation.webp https://thepharmadata.com/cvs-health-allocates-19-2-million-towards-affordable-housing-in-arvada-colorado/ 2024-04-25T04:38:11+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/CVS-Health-Allocates-19.2-Million-Towards-Affordable-Housing-in-Arvada-Colorado.webp https://thepharmadata.com/native-health-navigator-program-connects-tribes-to-cancer-care/ 2024-04-25T04:29:41+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Native-Health-Navigator-Program-Connects-Tribes-to-Cancer-Care.webp https://thepharmadata.com/vertex-treefrog-therapeutics-collaborate-to-enhance-cell-therapy-production-for-type-1-diabetes/ 2024-04-25T04:16:54+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Vertex-TreeFrog-Therapeutics-Collaborate-to-Enhance-Cell-Therapy-Production-for-Type-1-Diabetes.webp https://thepharmadata.com/roche-q1-sales-up-2-cer-both-divisions-show-high-single-digit-growth-excluding-covid-19/ 2024-04-25T04:08:40+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Roche-Q1-Sales-Up-2-CER-Both-Divisions-Show-High-Single-Digit-Growth-Excluding-COVID-19.webp https://thepharmadata.com/novel-malaria-treatment-shows-positive-results-for-infants-5kg-novartis-medicines-for-malaria-venture/ 2024-04-24T05:12:31+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Novel-Malaria-Treatment-Shows-Positive-Results-for-Infants-5kg-Novartis-Medicines-for-Malaria-Venture.webp https://thepharmadata.com/eu-approves-vaidya-as-additional-therapy-for-adults-with-pnh-and-persistent-haemolytic-anaemia-despite-rovelizumab-or-eculizumab-treatment/ 2024-04-24T05:09:09+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/EU-Approves-Vaidya-as-Additional-Therapy-for-Adults-with-PNH.webp https://thepharmadata.com/join-allergan-aesthetics-in-becoming-the-ambassador-for-botox-cosmetic-and-their-leading-brands/ 2024-04-24T05:02:53+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Join-Allergan-Aesthetics-in-Becoming-the-Ambassador-for-BOTOX%C2%AE-Cosmetic-and-Their-Leading-Brands.webp https://thepharmadata.com/positive-phase-2-results-for-nbi-1065845-in-adult-major-depression/ 2024-04-24T04:57:50+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Positive-Phase-2-Results-for-NBI-1065845-in-Adult-Major-Depression.webp https://thepharmadata.com/tomi-pitkaniemi-and-nikolas-kusto-discuss-how-effective-automation-boosts-medicinal-quality-and-orions-competitive-edge/ 2024-04-24T04:52:58+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Tomi-Pitkaniemi-and-Niklas-Kuusio-Discuss-How-Effective-Automation.webp https://thepharmadata.com/lupins-aurangabad-manufacturing-facility-granted-eir-by-u-s-fda/ 2024-04-24T04:47:50+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Lupins-Aurangabad-Manufacturing-Facility-Granted-EIR-by-U.S.-FDA.webp https://thepharmadata.com/moderna-secures-deal-to-provide-12-5-million-covid-19-vaccines-for-brazils-national-vaccination-drive/ 2024-04-23T04:50:15+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Moderna-Secures-Deal-to-Provide-12.5-Million-COVID-19-Vaccines-for-Brazils-National-Vaccination-Drive.webp https://thepharmadata.com/our-commitment-to-reducing-plastic-waste/ 2024-04-23T04:44:00+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Our-commitment-to-reducing-plastic-waste.webp https://thepharmadata.com/bristol-myers-squibb-cellares-strike-380m-deal-to-boost-car-t-cell-therapy-production/ 2024-04-23T04:40:07+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Bristol-Myers-Squibb-Cellares-Strike-380M-Deal-to-Boost-CAR-T-Cell-Therapy-Production.webp https://thepharmadata.com/european-commission-clears-pfizers-emblaveo-for-multidrug-resistant-infections/ 2024-04-23T04:35:03+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/European-Commission-Clears-Pfizers-EMBLAVEO%C2%AE-for-Multidrug-Resistant-Infections.webp https://thepharmadata.com/lilly-purchases-new-injectable-medicine-plant-from-nexus-pharmaceuticals/ 2024-04-23T04:23:28+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Lilly-Purchases-New-Injectable-Medicine-Plant-from-Nexus-Pharmaceuticals.webp https://thepharmadata.com/astellas-verifies-unfavourable-district-court-ruling-on-preliminary-injunction-against-lupin-and-zydus-myrbetriqtm-generics/ 2024-04-22T04:23:16+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Astellas-Verifies-Unfavourable-District-Court-Ruling-on-Preliminary-Injunction.webp https://thepharmadata.com/notice-from-nyse-american-received-by-novabay-pharmaceuticals-regarding-stockholder-equity/ 2024-04-20T06:16:10+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Notice-from-NYSE-American-Received-by-NovaBay-Pharmaceuticals-Regarding-Stockholder-Equity.webp https://thepharmadata.com/grifols-marks-50-years-of-transformative-plasma-medicine-production-in-clayton-n-c/ 2024-04-20T05:37:29+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Grifols-Marks-50-Years-of-Transformative-Plasma-Medicine-Production-in-Clayton-N.C.webp https://thepharmadata.com/shionogi-shows-fetcrojas-effectiveness-in-tough-infections-real-world-data/ 2024-04-20T05:30:40+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Shionogi-Shows-Fetcrojas-Effectiveness-in-Tough-Infections-Real-World-Data.webp https://thepharmadata.com/bayer-inks-renewable-energy-supply-deal-with-wuppertaler-stadtwerke/ 2024-04-20T05:19:07+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Bayer-Inks-Renewable-Energy-Supply-Deal-with-Wuppertaler-Stadtwerke.webp https://thepharmadata.com/fda-grants-approval-to-alecensa-as-the-primary-adjuvant-therapy-for-individuals-with-alk-positive-early-stage-non-small-cell-lung-cancer/ 2024-04-20T05:12:18+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/FDA-Grants-Approval-to-Alecensa-as-the-Primary-Adjuvant-Therapy-for-Individuals-with-ALK-Positive-Early-Stage-Non-Small-Cell-Lung-Cancer.webp https://thepharmadata.com/gepotidacin-promising-oral-treatment-for-uncomplicated-urogenital-gonorrhoea-in-phase-iii-data/ 2024-04-20T05:05:11+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Gepotidacin-Promising-Oral-Treatment-for-Uncomplicated-Urogenital.webp https://thepharmadata.com/jumar-bioincubator-pioneering-mini-brain-lab-on-a-chip-tech-to-create-australias-next-csl/ 2024-04-20T04:53:52+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Jumar-Bioincubator-Pioneering-Mini-Brain-Lab-on-a-Chip-Tech-to-Create-Australias-Next-CSL.webp https://thepharmadata.com/vertex-announces-advancements-of-suzetrigine-vx-548-in-acute-and-neuropathic-pain/ 2024-04-20T04:48:06+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Vertex-Announces-Advancements-of-Suzetrigine-VX-548-in-Acute-and-Neuropathic-Pain.webp https://thepharmadata.com/six-year-efficacy-of-novartis-kesimpta-in-relapsing-ms-treatment-naive-patients/ 2024-04-20T04:37:29+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Six-Year-Efficacy-of-Novartis-Kesimpta%C2%AE-in-Relapsing-MS-Treatment-Naive-Patients.webp https://thepharmadata.com/fda-greenlights-alecensa-by-roche-for-early-stage-alk-positive-lung-cancer/ 2024-04-20T04:30:30+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/FDA-Greenlights-Alecensa-by-Roche-for-Early-Stage-ALK-Positive-Lung-Cancer.webp https://thepharmadata.com/positive-outcomes-in-giant-cell-arteritis-patients-from-phase-3-select-gca-trial-of-upadacitinib-rinvoq/ 2024-04-20T04:23:03+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Positive-Outcomes-in-Giant-Cell-Arteritis-Patients-from-Phase-3.webp https://thepharmadata.com/building-climate-resilient-health-clinics/ 2024-04-20T04:19:12+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Building-climate-resilient-health-clinics.webp https://thepharmadata.com/next-generation-peptide-drugs-favor-synthetic-not-recombinant-manufacturing-2/ 2024-04-19T11:25:27+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/NEXT-GENERATION-PEPTIDE-DRUGS-FAVOR-SYNTHETIC-NOT-RECOMBINANT-MANUFACTURING-2.webp https://thepharmadata.com/supporting-save-the-children-finland-orions-donation-ensures-no-child-or-young-person-copes-alone/ 2024-04-19T11:20:28+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Supporting-Save-the-Children-Finland-Orions-Donation-Ensures-No-Child-or-Young-Person-Copes-Alone.webp https://thepharmadata.com/cerevel-therapeutics-reports-favorable-topline-findings-in-phase-3-adjunctive-study-of-tavapadon-for-parkinsons-disease-patients/ 2024-04-19T11:13:39+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Cerevel-Therapeutics-Reports-Favorable-Topline-Findings-in-Phase-3-Adjunctive-Study-of-Tavapadon-for-Parkinsons-Disease-Patients.webp https://thepharmadata.com/who-grants-prequalification-to-innovative-oral-cholera-vaccine/ 2024-04-19T11:09:07+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/WHO-Grants-Prequalification-to-Innovative-Oral-Cholera-Vaccine.webp https://thepharmadata.com/debut-of-whos-patient-safety-rights-charter-marks-milestone-in-healthcare/ 2024-04-19T11:06:21+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Debut-of-WHOs-Patient-Safety-Rights-Charter-Marks-Milestone-in-Healthcare.webp https://thepharmadata.com/updated-terminology-for-airborne-pathogens-released-by-leading-health-agencies/ 2024-04-19T11:02:56+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Updated-Terminology-for-Airborne-Pathogens-Released-by-Leading-Health-Agencies.webp https://thepharmadata.com/next-generation-peptide-drugs-favor-synthetic-not-recombinant-manufacturing/ 2024-04-18T05:18:34+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/NEXT-GENERATION-PEPTIDE-DRUGS-FAVOR-SYNTHETIC-NOT-RECOMBINANT-MANUFACTURING.webp https://thepharmadata.com/report-on-results-from-icmra-who-workshop-addressing-strain-changes-in-covid-19-vaccines/ 2024-04-18T05:08:51+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Report-on-Results-from-ICMRA-WHO-Workshop-Addressing-Strain-Changes-in-COVID-19-Vaccines.webp https://thepharmadata.com/fintlepla%e2%96%bc-fenfluramine-oral-solution-gains-approval-in-japan-as-adjunctive-therapy-for-seizures-linked-with-lennox-gastaut-syndrome-lgs/ 2024-04-18T05:00:41+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/FINTLEPLA%C2%AE%E2%96%BC-fenfluramine-oral-solution-gains-approval-in-Japan-as-adjunctive-therapy-for-seizures-linked-with-Lennox-Gastaut-syndrome-LGS.webp https://thepharmadata.com/merck-sparks-curiosity-2024-stem-careers-exploration-tour-with-the-curiosity-cube/ 2024-04-18T04:21:07+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Merck-Sparks-Curiosity-2024-STEM-Careers-Exploration-Tour-with-the-Curiosity-Cube.webp https://thepharmadata.com/jumar-bioincubator-launches-mission-crafting-australias-future-csl-with-mini-brains-and-lab-on-a-chip-wearables/ 2024-04-18T04:06:35+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Jumar-Bioincubator-Launches-Mission-Crafting-Australias-Future-CSL-with-Mini-Brains-and-Lab-on-a-Chip-Wearables.webp https://thepharmadata.com/48-week-phase-2-frexalimab-data-shows-promising-sustained-efficacy-in-ms/ 2024-04-18T04:01:42+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/48-Week-Phase-2-Frexalimab-Data-Shows-Promising-Sustained-Efficacy-in-MS.webp https://thepharmadata.com/six-year-efficacy-of-novartis-kesimpta-in-newly-diagnosed-relapsing-ms-patients/ 2024-04-18T03:55:33+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Six-Year-Efficacy-of-Novartis-Kesimpta%C2%AE-in-Newly-Diagnosed-Relapsing-MS-Patients.webp https://thepharmadata.com/astrazeneca-pioneers-advances-in-infectious-disease-protection-at-eccmid-2024/ 2024-04-18T03:45:52+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/AstraZeneca-Pioneers-Advances-in-Infectious-Disease-Protection-at-ECCMID-2024.webp https://thepharmadata.com/alert-falsified-contaminated-usp-ep-propylene-glycol-medical-product-alert-n1-2024/ 2024-04-16T10:33:02+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Alert-Falsified-Contaminated-USPEP-Propylene-Glycol-Medical-Product-Alert-N%C2%B012024-1.webp https://thepharmadata.com/viatris-appoints-corinne-le-goff-as-chief-commercial-officer/ 2024-04-16T04:43:04+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Viatris-Appoints-Corinne-Le-Goff-as-Chief-Commercial-Officer.webp https://thepharmadata.com/wuxi-biologics-chosen-for-sp-global-sustainability-yearbook-2024/ 2024-04-16T04:38:31+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/WuXi-Biologics-Chosen-for-SP-Global-Sustainability-Yearbook-2024.webp https://thepharmadata.com/labcorp-unveils-groundbreaking-blood-test-for-early-detection-of-neurodegenerative-diseases-and-brain-injuries/ 2024-04-16T04:32:11+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Labcorp-Unveils-Groundbreaking-Blood-Test-for-Early-Detection-of-Neurodegenerative-Diseases-and-Brain-Injuries.webp https://thepharmadata.com/fda-approves-tevimbra-for-advanced-esophageal-cancer-post-chemotherapy/ 2024-04-16T04:27:40+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/FDA-Approves-TEVIMBRA%C2%AE-for-Advanced-Esophageal-Cancer-Post-Chemotherapy.webp https://thepharmadata.com/novartis-fabhalta-iptacopan-reduces-proteinuria-by-38-3-in-iga-nephropathy-patients/ 2024-04-16T03:56:43+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Novartis-Fabhalta%C2%AE-iptacopan-reduces-proteinuria-by-38.3-in-IgA-Nephropathy-Patients.webp https://thepharmadata.com/unveiling-the-growing-impact-of-chronic-kidney-disease-on-patients-the-environment-and-economies/ 2024-04-16T03:50:55+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Kidney.webp https://thepharmadata.com/modalis-announces-partnership-with-ginkgo-bioworks/ 2024-04-15T04:45:21+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Modalis-Announces-Partnership-with-Ginkgo-Bioworks.webp https://thepharmadata.com/agenus-reveals-latest-phase-1-findings-and-advances-in-bot-bal-development-for-metastatic-mss-colorectal-cancer/ 2024-04-15T04:41:59+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Agenus-Reveals-Latest-Phase-1-Findings-and-Advances-in-BOTBAL-Development-for-Metastatic-MSS-Colorectal-Cancer.webp https://thepharmadata.com/revance-unveils-latest-daxxify-findings-at-the-2024-american-academy-of-neurology-annual-conference/ 2024-04-15T04:35:09+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Revance-Unveils-Latest-DAXXIFY%C2%AE-Findings-at-the-2024-American-Academy-of-Neurology-Annual-Conference.webp https://thepharmadata.com/dermal-fillers-market-2023-2035-hyaluronic-acid-innovation-drives-expansion-researchandmarkets-com/ 2024-04-15T04:30:50+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Hyaluronic-Acid.webp https://thepharmadata.com/comparison-study-shows-theracosbios-brenzavvy-matches-dapagliflozin-in-effectiveness-for-chinese-patients-with-type-2-diabetes/ 2024-04-15T04:22:24+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Comparison-Study-Shows-TheracosBios-BRENZAVVY%C2%AE-Matches-Dapagliflozin-in-Effectiveness-for-Chinese-Patients-with-Type-2-Diabetes.webp https://thepharmadata.com/fda-approves-ipsens-onivyde-as-promising-first-line-treatment-for-metastatic-pancreatic-adenocarcinoma/ 2024-04-15T04:10:48+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/FDA-Approves-Ipsens-Onivyde%C2%AE-as-Promising-First-Line-Treatment-for-Metastatic-Pancreatic-Adenocarcinoma.webp https://thepharmadata.com/ana-petry-utilizes-professional-expertise-to-navigate-life-after-personal-tragedy/ 2024-04-15T03:58:40+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Professional.webp https://thepharmadata.com/u-s-fda-conducts-inspection-of-lupins-dabhasa-facility-finds-no-observations/ 2024-04-13T05:36:01+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/U.S.-FDA-Conducts-Inspection-of-Lupins-Dabhasa-Facility-Finds-No-Observations.webp https://thepharmadata.com/strengthening-global-health-and-well-being-collaborative-efforts-between-who-and-the-netherlands/ 2024-04-13T05:24:47+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Collaborative.jpg https://thepharmadata.com/nigeria-leads-globally-with-introduction-of-revolutionary-5-in-1-meningitis-vaccine/ 2024-04-13T05:21:39+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Nigeria-Leads-Globally-with-Introduction-of-Revolutionary-5-in-1-Meningitis-Vaccine.webp https://thepharmadata.com/jazz-pharmaceuticals-to-present-comprehensive-neuroscience-portfolio-at-annual-american-academy-of-neurology-meeting/ 2024-04-13T05:13:06+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Jazz-Pharmaceuticals-to-Showcase-Expansive-Neuroscience-Portfolio-at-American-Academy-of-Neurology-Annual-Meeting.webp https://thepharmadata.com/zatolmilast-receives-orphan-medicinal-product-designation-from-the-european-commission-promising-first-in-class-therapy-for-fragile-x-syndrome/ 2024-04-13T05:02:44+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Zatolmilast-Receives-Orphan-Medicinal-Product-Designation-from-the-European-Commission-Promising-First-in-Class-Therapy-for-Fragile-X-Syndrome.webp https://thepharmadata.com/baxter-broadens-pharmaceutical-portfolio-with-fresh-injectable-offerings-in-the-u-s/ 2024-04-13T04:55:22+00:00 https://thepharmadata.com/update-intangible-asset-impairment-contingent-consideration-fair-value-fy2023-financial-forecast-revision/ 2024-04-13T04:48:46+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Update-Intangible-Asset-Impairment-Contingent-Consideration-Fair-Value-FY2023-Financial-Forecast-Revision.webp https://thepharmadata.com/walgreens-pharmacist-honored-as-advocate-for-minority-health/ 2024-04-13T04:41:30+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Walgreens-Pharmacist-Honored-as-Advocate-for-Minority-Health.webp https://thepharmadata.com/commencement-of-novartis-tender-offer-for-morphosys-ag/ 2024-04-13T04:29:08+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Commencement-of-Novartis-Tender-Offer-for-MorphoSys-AG.webp https://thepharmadata.com/fda-grants-roche-breakthrough-device-designation-for-blood-test-advancing-early-alzheimers-disease-detection/ 2024-04-13T04:16:44+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Disease-2.webp https://thepharmadata.com/abbvies-new-data-confirms-atogepant-qulipta-for-long-term-migraine-prevention/ 2024-04-13T04:12:02+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Migraine.webp https://thepharmadata.com/orion-research-assistants-striving-to-combat-cancer-and-alleviate-pain-our-breakthrough-discovery-holds-promise-for-shaping-future-research/ 2024-04-11T05:06:56+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Orion-Research-Assistants-Striving-to-Combat-Cancer-and-Alleviate-Pain-1.webp https://thepharmadata.com/jazz-pharmaceuticals-set-to-unveil-broad-range-of-neuroscientific-innovations-at-american-academy-of-neurologys-annual-gathering/ 2024-04-11T04:56:36+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Jazz-Pharmaceuticals-Set-to-Unveil-Broad-Range-of-Neuroscientific.webp https://thepharmadata.com/fda-grants-emergency-use-authorization-to-labcorp-for-home-collection-of-mpox-pcr-test/ 2024-04-11T04:38:49+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/FDA-Grants-Emergency-Use-Authorization-to-Labcorp-for-Home-Collection-of-Mpox-PCR-Test.webp https://thepharmadata.com/vertex-strikes-deal-to-purchase-alpine-immune-sciences/ 2024-04-11T04:31:24+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Vertex-Strikes-Deal-to-Purchase-Alpine-Immune-Sciences.webp https://thepharmadata.com/selecting-the-ideal-allergy-medication-for-your-seasonal-symptoms/ 2024-04-11T04:30:33+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Selecting-the-Ideal-Allergy-Medication-for-Your-Seasonal-Symptoms.webp https://thepharmadata.com/world-health-organization-raises-concern-over-viral-hepatitis-3500-lives-lost-daily/ 2024-04-10T03:58:04+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/World-Health-Organization-Raises-Concern-Over-Viral-Hepatitis-3500-Lives-Lost-Daily.webp https://thepharmadata.com/who-to-release-new-guidelines-for-simultaneous-treatment-of-drug-resistant-tuberculosis-and-hepatitis-c/ 2024-04-10T03:53:10+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/WHO-to-Release-New-Guidelines-for-Simultaneous-Treatment-of-Drug-Resistant-Tuberculosis-and-Hepatitis-C.webp https://thepharmadata.com/tevas-first-quarter-2024-financial-results-conference-call-scheduled-for-may-8th-at-8-a-m-et/ 2024-04-10T03:41:37+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Tevas-First-Quarter-2024-Financial-Results-Conference-Call-Scheduled-for-May-8th-at-8-a.m.-ET.webp https://thepharmadata.com/pfizer-reveals-encouraging-phase-3-findings-of-abrysvo-in-high-risk-adults-ages-18-59-vulnerable-to-rsv-disease/ 2024-04-10T03:22:43+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Pfizer-Reveals-Encouraging-Phase-3-Findings-of-ABRYSVO%C2%AE-in-High-Risk-Adults-Ages-18-59-Vulnerable-to-RSV-Disease.webp https://thepharmadata.com/skinmedica-revolutionizes-acne-care-for-clear-skin-confidence/ 2024-04-10T03:17:06+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/SkinMedica%C2%AE-Revolutionizes-Acne-Care-for-Clear-Skin-Confidence-e1772258681223.webp https://thepharmadata.com/bridgebio-pharma-cmr-imaging-supports-clinical-improvement-in-attr-cm-trial/ 2024-04-08T04:29:59+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/BridgeBio-Pharma-CMR-Imaging-Supports-Clinical-Improvement-in-ATTR-CM-Trial.webp https://thepharmadata.com/ionis-reveals-encouraging-findings-from-phase-3-balance-trial-of-olezarsen-in-familial-chylomicronemia-syndrome/ 2024-04-08T04:25:39+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Ionis-Reveals-Encouraging-Findings-from-Phase-3-Balance-Trial-of-Olezarsen-in-Familial-Chylomicronemia-Syndrome.webp https://thepharmadata.com/al-shifa-hospital-reduced-to-ruins-after-six-months-of-war-finds-who-mission/ 2024-04-08T04:18:52+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Al-Shifa-Hospital-Reduced-to-Ruins-After-Six-Months-of-War-Finds-WHO-Mission.webp https://thepharmadata.com/tevas-latest-pharmacokinetic-modeling-data-shows-uzedy-benefits-for-schizophrenia-patients-at-sirs-2024/ 2024-04-08T04:08:42+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Tevas-Latest-Pharmacokinetic-Modeling-Data-Shows-UZEDY%C2%AE-Benefits-for-Schizophrenia-Patients-at-SIRS-2024.webp https://thepharmadata.com/positive-findings-zilebesiran-combined-with-antihypertensives-for-uncontrolled-hypertension/ 2024-04-08T03:59:08+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Positive-Findings-Zilebesiran-Combined-with-Antihypertensives-for-Uncontrolled-Hypertension.webp https://thepharmadata.com/study-mrna-immunotherapy-shows-long-term-immune-response-and-delayed-tumor-return-in-pancreatic-cancer-patients/ 2024-04-08T03:53:36+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Study-mRNA-Immunotherapy-Shows-Long-Term-Immune-Response-and-Delayed-Tumor-Return-in-Pancreatic-Cancer-Patients.webp https://thepharmadata.com/icon-announces-cfo-transition/ 2024-04-05T11:22:28+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/ICON-Announces-CFO-Transition.webp https://thepharmadata.com/novartis-to-seek-pre-taxane-label-expansion-for-pluvicto-in-second-half-of-2024-following-latest-data-from-phase-iii-psmafore-trial/ 2024-04-05T11:00:58+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Novartis-to-Seek-Pre-Taxane-Label-Expansion-for-Pluvicto%C2%AE-in-Second-Half-of-2024-Following-Latest-Data-from-Phase-III-PSMAfore-Trial-2.webp https://thepharmadata.com/imfinzi-boosts-survival-in-limited-stage-small-cell-lung-cancer-adriatic-trial-results/ 2024-04-05T10:47:29+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Imfinzi-Boosts-Survival-in-Limited-Stage-Small-Cell-Lung-Cancer-ADRIATIC-Trial-Results.webp https://thepharmadata.com/phase-3-trial-mercks-mk-1084-oral-kras-g12c-inhibitor-with-keytruda-for-metastatic-non-small-cell-lung-cancer/ 2024-04-05T10:43:30+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Phase-3-Trial-Mercks-MK-1084-Oral-KRAS-G12C-Inhibitor-with-KEYTRUDA%C2%AE-for-Metastatic-Non-Small-Cell-Lung-Cancer.webp https://thepharmadata.com/bristol-myers-squibb-unveils-2023-environmental-social-and-governance-report-highlighting-advancements-and-establishing-future-objectives/ 2024-04-03T11:08:39+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Bristol-Myers-Squibb-Unveils-2023-Environmental-Social-and-Governance-Report-Highlighting-Advancements-and-Establishing-Future-Objectives.webp https://thepharmadata.com/eu-widens-approval-for-bristol-myers-squibbs-reblozyl-for-first-line-lr-mds-anemia/ 2024-04-03T11:04:06+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/EU-Widens-Approval-for-Bristol-Myers-Squibbs-Reblozyl%C2%AE-for-First-Line-LR-MDS-Anemia.webp https://thepharmadata.com/us-accepts-biologics-license-application-for-datopotamab-deruxtecan-in-advanced-hr-positive-her2-negative-breast-cancer-post-prior-treatment/ 2024-04-03T10:11:03+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/US-Accepts-Biologics-License-Application-for-Datopotamab-Deruxtecan-in-Advanced-HR-Positive-HER2-Negative-Breast-Cancer-Post-Prior-Treatment.webp https://thepharmadata.com/wuxi-biologics-sweeps-2024-cdmo-leadership-awards-across-the-board/ 2024-04-03T09:59:48+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/WuXi-Biologics-Sweeps-2024-CDMO-Leadership-Awards-Across-the-Board.webp https://thepharmadata.com/fda-approves-astellas-supplemental-new-drug-application-for-izervay-to-treat-geographic-atrophy/ 2024-04-01T04:41:16+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/FDA-Approves-Astellas-Supplemental-New-Drug-Application-for-IZERVAY%E2%84%A2-to-Treat-Geographic-Atrophy.webp https://thepharmadata.com/eisai-seeks-fda-approval-for-iv-maintenance-dosing-of-leqembi-in-early-alzheimers-treatment/ 2024-04-01T04:34:02+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Eisai-Seeks-FDA-Approval-for-IV-Maintenance-Dosing-of-LEQEMBI%C2%AE-in-Early-Alzheimers-Treatment.webp https://thepharmadata.com/avian-influenza-epidemics-in-2023/ 2024-04-01T04:13:52+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Avian-Influenza-Epidemics-in-2023.webp https://thepharmadata.com/swine-influenza-outbreaks-in-2023/ 2024-04-01T04:09:49+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Swine-Influenza-Outbreaks-in-2023.webp https://thepharmadata.com/progress-in-clinical-development-of-efgartigimod-for-primary-sjogrens-disease-by-argenx/ 2024-03-30T07:32:13+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Progress-in-Clinical-Development-of-Efgartigimod-for-Primary-Sjogrens-Disease-by-Argenx.webp https://thepharmadata.com/cvs-health-allocates-over-3-million-to-organizations-enhancing-health-outcomes-in-phoenix/ 2024-03-30T05:09:11+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/CVS-Health%C2%AE-Allocates-Over-3-Million-to-Organizations-Enhancing-Health-Outcomes-in-Phoenix.webp https://thepharmadata.com/bristol-myers-squibb-confirms-success-of-krazati-trial-in-kras-g12c-mutated-lung-cancer/ 2024-03-30T05:03:45+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Bristol-Myers-Squibb-Confirms-Success-of-KRAZATI-Trial-in-KRAS-G12C-Mutated-Lung-Cancer.webp https://thepharmadata.com/bristol-myers-squibb-updates-phase-3-yellowstone-trial-progress-oral-zeposia-ozanimod-evaluation-in-moderate-to-severe-active-crohns-disease-patients/ 2024-03-29T09:21:57+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Bristol-Myers-Squibb-Updates-Phase-3-YELLOWSTONE-Trial-Progress-Oral-Zeposia-Ozanimod-Evaluation-in-Moderate-to-Severe-Active-Crohns-Disease-Patients.webp https://thepharmadata.com/bristol-myers-squibb-broadens-health-equity-grant-programs-for-enhanced-health-results/ 2024-03-29T09:13:55+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Bristol-Myers-Squibb-Broadens-Health-Equity-Grant-Programs-for-Enhanced-Health-Results.webp https://thepharmadata.com/bristol-myers-squibb-presents-new-cardiovascular-findings-at-2024-acc-conference-strengthening-evidence-base/ 2024-03-29T09:07:18+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Bristol-Myers-Squibb-Presents-New-Cardiovascular-Findings-at-2024-ACC-Conference-Strengthening-Evidence-Base.webp https://thepharmadata.com/fda-approves-roches-groundbreaking-molecular-test-for-malaria-screening-in-blood-donors/ 2024-03-29T08:48:38+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/FDA-Approves-Roches-Groundbreaking-Molecular-Test-for-Malaria-Screening-in-Blood-Donors.webp https://thepharmadata.com/eu-greenlights-mercks-keytruda-combo-for-high-risk-nsclc-treatment/ 2024-03-29T08:43:06+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Treatment-2.webp https://thepharmadata.com/breakthrough-fda-approval-mercks-winrevair-revolutionizes-pah-treatment-for-adults/ 2024-03-29T08:35:04+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Breakthrough-FDA-Approval-Mercks-WINREVAIR%E2%84%A2-Revolutionizes-PAH-Treatment-for-Adults.webp https://thepharmadata.com/abbvies-acquisition-of-landos-biopharma-bolsters-its-reach-in-inflammatory-and-autoimmune-conditions/ 2024-03-29T08:24:15+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/AbbVies-Acquisition-of-Landos-Biopharma-Bolsters-its-Reach-in-Inflammatory-and-Autoimmune-Conditions.webp https://thepharmadata.com/novo-nordisks-acquisition-of-cardior-pharmaceuticals-enhancing-cardiovascular-disease-pipeline/ 2024-03-29T07:25:03+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Novo-Nordisks-Acquisition-of-Cardior-Pharmaceuticals-Enhancing-Cardiovascular-Disease-Pipeline.webp https://thepharmadata.com/awiqli-european-authorities-recommend-approval-for-weekly-basal-insulin-icodec-in-diabetes-treatment/ 2024-03-29T07:17:46+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Awiqli%C2%AE-European-Authorities-Recommend-Approval-for-Weekly-Basal-Insulin-Icodec-in-Diabetes-Treatment.webp https://thepharmadata.com/comprehensive-research-on-the-global-covid-19-diagnostic-market-for-2024-executive-and-consultant-guides-available-researchandmarkets-com/ 2024-03-23T06:52:51+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Global-Covid-19-Diagnostic-Market-Research-2024.webp https://thepharmadata.com/gilead-sciences-announces-completion-of-acquisition-of-cymabay/ 2024-03-23T06:47:25+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Gilead-Sciences-Announces-Completion-of-Acquisition-of-CymaBay.webp https://thepharmadata.com/gensight-biologics-releases-comprehensive-financial-summary-for-fiscal-year-2023/ 2024-03-23T06:43:52+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/GenSight-Biologics-Releases-Comprehensive-Financial-Summary-for-Fiscal-Year-2023.webp https://thepharmadata.com/2024-biopharma-site-network-pulse-report-insights-from-iqvia-icon-parexel-fortrea-ppd-thermo-fisher-and-syneos-health-research-and-markets-com/ 2024-03-23T06:39:28+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Research-2.webp https://thepharmadata.com/otsuka-pharmas-indonesian-subsidiaries-earn-exemplar-award-from-ewtb-for-tuberculosis-eradication-efforts/ 2024-03-23T06:36:04+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Otsuka-Pharmas-Indonesian-Subsidiaries-Earn-Exemplar.webp https://thepharmadata.com/chmp-recommends-novartis-fabhalta-for-adult-paroxysmal-nocturnal-hemoglobinuria-pnh/ 2024-03-23T06:09:12+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/CHMP-Recommends-Novartis-Fabhalta%C2%AE-for-Adult-Paroxysmal-Nocturnal-Hemoglobinuria-PNH.webp https://thepharmadata.com/fda-fully-approves-elahere-for-specific-ovarian-cancer-patients/ 2024-03-23T06:04:30+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/FDA-Fully-Approves-ELAHERE%C2%AE-for-Specific-Ovarian-Cancer-Patients.webp https://thepharmadata.com/ono-collaborates-with-university-of-oxford-for-extensive-drug-discovery-partnership/ 2024-03-23T06:01:02+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Ono-Collaborates-with-University-of-Oxford-for-Extensive-Drug-Discovery-Partnership.webp https://thepharmadata.com/wuxi-biologics-named-to-cdp-a-list-for-water-security/ 2024-03-23T05:51:10+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/WuXi-Biologics-Named-to-CDP-%E2%80%98A-List-for-Water-Security.webp https://thepharmadata.com/bio-techne-attains-european-ivdr-certification-for-diagnostic-test-monitoring-chronic-myeloid-leukemia/ 2024-03-23T05:46:50+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Bio-Techne-Attains-European-IVDR-Certification-for-Diagnostic-Test-Monitoring-Chronic-Myeloid-Leukemia.webp https://thepharmadata.com/ucbs-bimzelx%e2%96%bc-bimekizumab-gains-favorable-chmp-opinion-for-treatment-moderate-to-severe-hidradenitis-suppurativa-in-adults/ 2024-03-23T04:28:13+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/UCBs-BIMZELX%C2%AE%E2%96%BC-bimekizumab-Gains-Favorable-CHMP-Opinion-for-treatment-Moderate-to-Severe-Hidradenitis-Suppurativa-in-Adults.webp https://thepharmadata.com/bayer-and-trinity-agtech-collaborate-to-advance-regenerative-agriculture-practices/ 2024-03-23T04:10:57+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Bayer-and-Trinity-Agtech-Collaborate-to-Advance-Regenerative-Agriculture-Practices.webp https://thepharmadata.com/legend-biotech-releases-debut-environmental-social-and-governance-esg-report/ 2024-03-21T05:14:04+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Biotech-Releases.webp https://thepharmadata.com/viatris-announces-closure-of-global-research-and-development-collaboration-with-idorsia-official-statement/ 2024-03-21T05:13:41+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Viatris-Announces-Closure-of-Global-Research-and-Development.webp https://thepharmadata.com/labcorp-introduces-ptau217-blood-test-for-faster-alzheimers-diagnosis-and-clinical-trial-support/ 2024-03-21T05:13:14+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Labcorp-Introduces-pTau217-Blood-Test-for-Faster-Alzheimers-Diagnosis-and-Clinical-Trial-Support.webp https://thepharmadata.com/pfizer-reports-encouraging-overall-survival-results-in-phase-3-study-of-adcetris-treatment-for-relapsed-refractory-diffuse-large-b-cell-lymphoma/ 2024-03-21T05:12:54+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Pfizer-Reports-Encouraging-Overall-Survival-Results-in-Phase-3-Study-of-ADCETRIS%C2%AE-Treatment-for-RelapsedRefractory-Diffuse-Large-B-cell-Lymphoma.webp https://thepharmadata.com/wuxi-biologics-commences-construction-on-crdmo-facility-in-singapore/ 2024-03-21T04:50:42+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/WuXi-Biologics-Commences-Construction-on-CRDMO-Facility-in-Singapore.webp https://thepharmadata.com/dating-a-person-in-her-50s/ 2024-03-18T16:42:37+00:00 https://thepharmadata.com/roche-annual-general-meeting-2024/ 2024-03-16T06:48:50+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Roche-Annual-General-Meeting-2024.webp https://thepharmadata.com/keytruda-boosts-survival-in-high-risk-locally-advanced-cervical-cancer/ 2024-03-16T06:32:24+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/KEYTRUDA%C2%AE-Boosts-Survival-in-High-Risk-Locally-Advanced-Cervical-Cancer.webp https://thepharmadata.com/merck-unveils-clinical-trial-strategy-for-new-hpv-vaccine-and-gardasil9-single-dose-regimen/ 2024-03-16T06:25:11+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Merck-Unveils-Clinical-Trial-Strategy-for-New-HPV-Vaccine-and-GARDASIL%C2%AE9-Single-Dose-Regimen.webp https://thepharmadata.com/hansoh-pharma-enhances-collaboration-with-biotheus-to-advance-development-of-egfr-cmet-bispecific-antibody-drug-conjugates/ 2024-03-16T06:19:26+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Hansoh-Pharma-Expanded-Their-Partnership-with-Biotheus-for-Developing-EGFRcMET-Bispecific-Antibody-Drug-Conjugates.webp https://thepharmadata.com/update-consultation-by-who-experts-revising-toxic-equivalency-factors-for-dioxin-like-compounds-and-selected-polychlorinated-biphenyls/ 2024-03-16T06:06:53+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/WHO-and-UNICEF-launch-free-online-course-to-address-childrens-environmental-health.webp https://thepharmadata.com/neurological-conditions-impact-over-1-in-3-individuals-ranking-as-the-primary-cause-of-global-illness-and-disability/ 2024-03-16T05:54:40+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Neurological-Conditions-Impact-Over-1-in-3-Individuals-Ranking-as-the-Primary-Cause-of-Global-Illness-and-Disability.webp https://thepharmadata.com/who-and-unicef-introduce-complimentary-online-course-on-childrens-environmental-health/ 2024-03-16T05:46:41+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/WHO-and-UNICEF-launch-free-online-course-to-address-childrens-environmental-health-1.webp https://thepharmadata.com/gender-disparities-unveiled-the-core-of-the-worldwide-health-and-care-work-crisis-according-to-who-report/ 2024-03-16T05:38:39+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Health-and-Care.webp https://thepharmadata.com/ionis-reports-encouraging-findings-from-phase-2-trial-of-ion224-showing-clinical-effectiveness-in-nash-mash-treatment/ 2024-03-16T05:30:06+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Ionis-announces-positive-results-from-Phase-2-study-of-ION224-an-investigational-2.webp https://thepharmadata.com/lupin-receives-approval-from-u-s-fda-for-doxycycline-for-injection-usp/ 2024-03-16T04:55:58+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Lupin-Receives-Approval-from-U.S.-FDA-for-Doxycycline-for-Injection-USP.webp https://thepharmadata.com/the-chemical-quality-control-laboratory-guardian-of-standards-in-the-pharmaceutical-plant/ 2024-03-16T04:51:11+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/The-Chemical-Quality-Control-Laboratory-Guardian-of-Standards-in-the-Pharmaceutical-Plant-1.webp https://thepharmadata.com/blueprint-medicines-unveils-inducement-grants-in-accordance-with-nasdaq-listing-rule-5635/ 2024-03-16T04:43:40+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Blueprint-Medicines-Unveils-Inducement-Grants-in-Accordance-with-Nasdaq-Listing-Rule-5635.webp https://thepharmadata.com/crispr-therapeutics-nominates-addition-to-board-of-directors/ 2024-03-16T04:43:24+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/CRISPR-Therapeutics-Nominates-Addition-to-Board-of-Directors.webp https://thepharmadata.com/optimizing-project-management-for-pharmaceutical-manufacturing-a-roadmap-to-effective-clinical-trials/ 2024-03-16T04:43:05+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Optimizing-Project-Management-for-Pharmaceutical-Manufacturing-A-Roadmap-to-Effective-Clinical-Trials.webp https://thepharmadata.com/bimekizumab-phase-3-sustained-improvements-in-hidradenitis-suppurativa/ 2024-03-11T06:24:57+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Bimekizumab-Phase-3-Sustained-Improvements-in-Hidradenitis-Suppurativa.webp https://thepharmadata.com/amgen-presents-new-research-on-otezla-apremilast-at-aad-2024/ 2024-03-11T05:46:08+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/AMGEN-PRESENTS-NEW-RESEARCH-ON-OTEZLA%C2%AE-APREMILAST-AT-AAD-2024.webp https://thepharmadata.com/wegovy-approved-in-us-to-lower-cardiovascular-risk-in-overweight-or-obese-individuals-with-existing-heart-conditions/ 2024-03-11T05:36:34+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Wegovy%C2%AE-Approved-in-US-to-Lower-Cardiovascular-Risk-in-Overweight-or-Obese-Individuals-with-Existing-Heart-Conditions.webp https://thepharmadata.com/a-first-of-its-kind-study-shows-skin-improvement-in-over-two-thirds-of-people-with-atopic-dermatitis-and-skin-of-color-using-lebrikizumab/ 2024-03-11T05:15:06+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/FDA-to-Host-Advisory-Committee-Meeting-on-Donanemabs-TRAILBLAZER-ALZ-2-Study-1.webp https://thepharmadata.com/fda-to-host-advisory-committee-meeting-on-donanemabs-trailblazer-alz-2-study/ 2024-03-11T05:10:45+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/FDA-to-Host-Advisory-Committee-Meeting-on-Donanemabs-TRAILBLAZER-ALZ-2-Study.webp https://thepharmadata.com/argonaut-manufacturing-services-boosts-aseptic-pharma-filling-with-45m-investment/ 2024-03-11T05:04:18+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Argonaut-Manufacturing-Services-Expands-Aseptic-Pharmaceutical-Fill-Finish-Capabilities-with-45-Million-Equity-Investment-from-NewVale-Capital-and-Telegraph-Hill-Partners.webp https://thepharmadata.com/gossamer-bios-2023-financial-report-and-business-update/ 2024-03-11T05:04:02+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Gossamer-Bio-Announces-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Business-Update.webp https://thepharmadata.com/oragenics-inc-readies-phase-ii-clinical-trials-for-concussion-treatment-drug/ 2024-03-11T05:03:29+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Oragenics-Inc.-Prepares-Drug-for-Phase-II-Clinical-Trials-to-Treat-Concussion.webp https://thepharmadata.com/mirum-pharmaceuticals-scheduled-to-attend-upcoming-investor-conferences/ 2024-03-11T05:02:58+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Mirum-Pharmaceuticals-to-Participate-in-Upcoming-Investor-Conferences.webp https://thepharmadata.com/alnylams-kardia-2-study-shows-zilebesiran-adds-significant-blood-pressure-reduction/ 2024-03-07T10:15:09+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Alnylam-Reports-Positive-KARDIA-2-Topline-Study-Results-Demonstrating-Clinically-Significant-Blood-Pressure-Reductions-When-Zilebesiran-is-Added-to-Standard-of-Care-Antihypertensives.webp https://thepharmadata.com/aktana-unveils-advanced-omnichannel-tools-for-med-tech-firms/ 2024-03-07T09:39:21+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Aktana-Announces-Release-of-Next-Generation-Omnichannel-Orchestration-Tools-Designed-for-Medical-Technology-Companies.webp https://thepharmadata.com/summit-therapeutics-at-barclays-26th-global-healthcare-conference/ 2024-03-07T09:30:37+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Summit-Therapeutics-to-Present-at-the-Barclays-1.webp https://thepharmadata.com/2032-myocardial-infarction-treatment-insights-farxiga-forecast-researchandmarkets-com/ 2024-03-07T09:19:05+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/FARXIGA-Market-Insights-and-Advanced-Forecast-Report-Reveal-Critical-Developments-in-Myocardial-Infarction-Treatment-by-2032-ResearchAndMarkets.com_.webp https://thepharmadata.com/mercks-involvement-confirmed-for-the-barclays-26th-annual-global-healthcare-conference/ 2024-03-07T09:13:35+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Merck-to-Participate-in-the-Barclays-26th-Annual-Global-Healthcare-Conference.webp https://thepharmadata.com/expanded-collaboration-for-neoantigen-cancer-vaccine-trial/ 2024-03-07T09:06:44+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Transgene-NEC-and-BostonGene-Expand-Collaboration-for-Phase-III-Clinical-Trial-of-Neoantigen-Cancer-Vaccine-TG4050.webp https://thepharmadata.com/united-therapeutics-corporation-scheduled-to-participate-in-the-leerink-partners-global-biopharma-conference-2024/ 2024-03-07T09:00:41+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/United-Therapeutics-Corporation-to-Present-at-the-Leerink-Partners-Global-Biopharma-Conference-2024.jpg https://thepharmadata.com/successful-large-scale-gmp-manufacturing-of-mov18-ige-antibody-for-ovarian-cancer-by-epsilogen-and-lonza/ 2024-03-07T08:54:32+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Epsilogen-and-Lonza-Announce-Successful-Large-Scale-GMP-Manufacturing-of-MOv18-an-IgE-Antibody-Targeting-Ovarian-Cancer-1.webp https://thepharmadata.com/pda-india-chapter-annual-meeting-ensuring-quality-compliance-in-pharma-manufacturing-and-regulatory-standards-march-11-15-hyderabad-india/ 2024-03-04T07:27:31+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/PDA-India-Chapter-Annual-Meeting-Ensuring-Quality-Compliance-in-Pharma-Manufacturing-and-Regulatory-Standards-%E2%80%93-March-11-15-Hyderabad-India.webp https://thepharmadata.com/vivani-medical-announces-pricing-of-15-0-million-registered-direct-offering-of-common-stock-and-warrants/ 2024-03-04T07:20:50+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Vivani-Medical-Announces-Pricing-of-15.0-Million-Registered-Direct-Offering-of-Common-Stock-and-Warrants.webp https://thepharmadata.com/shionogi-and-osaka-university-establish-a-new-joint-research-lab-on-post-covid-19-condition-long-covid/ 2024-03-04T06:59:03+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Shionogi-and-Osaka-University-Establish-a-New-Joint-Research-Lab-on-Post-COVID-19-Condition-Long-COVID.jpg https://thepharmadata.com/bio-techne-releases-second-quarter-fiscal-2024-results/ 2024-03-04T06:58:39+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/BIO-TECHNE-RELEASES-SECOND-QUARTER-FISCAL-2024-RESULTS.webp https://thepharmadata.com/shionogi-and-nagasaki-university-launch-second-phase-of-collaborative-effort-in-combatting-malaria-and-infectious-diseases/ 2024-03-04T06:52:06+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Shionogi-Announces-the-Initiation-of-the-Second-Phase-of-Comprehensive-Cooperation-in-the-Field-of-Infectious-Diseases.webp https://thepharmadata.com/wuxi-biologics-ireland-site-receives-three-iso-certifications/ 2024-03-04T06:40:41+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/WuXi-Biologics-Ireland-Site-Receives-Three-ISO-Certifications.webp https://thepharmadata.com/astellas-launches-phase-3-trials-of-fezolinetant-for-menopausal-symptom-relief-in-japan/ 2024-03-04T04:45:25+00:00 https://thepharmadata.com/wp-content/uploads/2024/03/Astellas-Initiates-Phase-3-Clinical-Studies-of-Fezolinetant-for-VMS-Associated-with-Menopause-in-Japan.webp https://thepharmadata.com/xolair-reduces-allergic-reactions-to-multiple-foods-nejm-study/ 2024-02-28T11:58:25+00:00 https://thepharmadata.com/wp-content/uploads/2024/02/Xolair-Reduces-Allergic-Reactions-to-Multiple-Foods-NEJM-Study.webp https://thepharmadata.com/abbvie-and-ose-immunotherapeutics-collaborate-to-advance-novel-monoclonal-antibody-for-chronic-inflammation-treatment/ 2024-02-28T11:54:10+00:00 https://thepharmadata.com/wp-content/uploads/2024/02/AbbVie-and-OSE-Immunotherapeutics-Collaborate-to-Advance-Novel-Monoclonal-Antibody-for-Chronic-Inflammation-Treatment.webp https://thepharmadata.com/fda-prioritizes-review-of-epkinly-for-tough-follicular-lymphoma-cases/ 2024-02-28T11:49:20+00:00 https://thepharmadata.com/wp-content/uploads/2024/02/FDA-Prioritizes-Review-of-EPKINLY%C2%AE-for-Tough-Follicular-Lymphoma-Cases.webp https://thepharmadata.com/chmp-grants-positive-opinion-to-vertex-for-kalydeco-in-treating-cystic-fibrosis-in-infants-aged-1-month-and-above/ 2024-02-24T06:11:24+00:00 https://thepharmadata.com/wp-content/uploads/2024/02/CHMP-Grants-Positive-Opinion-to-Vertex-for-KALYDECO%C2%AE-in-Treating-Cystic-Fibrosis-in-Infants-Aged-1-Month-and-Above.webp https://thepharmadata.com/bristol-myers-squibbs-reblozyl-luspatercept-receives-positive-chmp-opinion-for-anemia-treatment-in-low-to-intermediate-risk-mds-adults/ 2024-02-24T06:02:17+00:00 https://thepharmadata.com/wp-content/uploads/2024/02/Bristol-Myers-Squibbs-Reblozyl%C2%AE-luspatercept-Receives-Positive-CHMP-Opinion-for-Anemia-Treatment-in-Low-to-Intermediate-Risk-MDS-Adults.webp https://thepharmadata.com/celltrion-reveals-new-two-year-results-of-subcutaneous-infliximab-ct-p13-sc-for-treating-inflammatory-bowel-disease-ibd-at-19th-ecco-congress/ 2024-02-24T05:28:02+00:00 https://thepharmadata.com/wp-content/uploads/2024/02/Disease.webp https://thepharmadata.com/ironwood-pharmaceuticals-to-showcase-four-abstracts-at-aspens-2024-nutrition-science-practice-conference/ 2024-02-24T05:20:18+00:00 https://thepharmadata.com/wp-content/uploads/2024/02/Ironwood-Pharmaceuticals-to-Showcase-Four-Abstracts-at-ASPENs-2024.webp https://thepharmadata.com/bristol-myers-squibb-reports-conclusion-of-rayzebio-tender-offer-period/ 2024-02-24T05:13:19+00:00 https://thepharmadata.com/wp-content/uploads/2024/02/Bristol-Myers-Squibb-Reports-Conclusion-of-RayzeBio-Tender-Offer-Period.webp https://thepharmadata.com/fda-prioritizes-review-of-dupixent-sable-for-copd-treatment-targeting-type-2-inflammation/ 2024-02-24T05:06:50+00:00 https://thepharmadata.com/wp-content/uploads/2024/02/FDA-Prioritizes-Review-of-Dupixent%C2%AE-sBLA-for-COPD-Treatment-Targeting-Type-2-Inflammation.webp https://thepharmadata.com/sanofis-board-of-directors-recommends-clotilde-delbos-anne-francoise-nesmes-and-john-sundy-as-independent-directors/ 2024-02-24T04:57:53+00:00 https://thepharmadata.com/wp-content/uploads/2024/02/Sanofis-Board-of-Directors-Recommends-Clotilde-Delbos-Anne-Francoise-Nesmes-and-John-Sundy-as-Independent-Directors.webp https://thepharmadata.com/acquisition-of-gracell-completed/ 2024-02-24T04:53:33+00:00 https://thepharmadata.com/wp-content/uploads/2024/02/Acquisition-of-Gracell-completed.webp https://thepharmadata.com/keytruda-granted-favorable-eu-chmp-opinion-for-nsclc-treatment/ 2024-02-24T04:48:46+00:00 https://thepharmadata.com/wp-content/uploads/2024/02/KEYTRUDA%C2%AE-Granted-Favorable-EU-CHMP-Opinion-for-NSCLC-Treatment.webp https://thepharmadata.com/abbvie-and-tentarix-partner-to-innovate-conditional-multi-specific-biologics-for-oncology-and-immunology/ 2024-02-24T04:43:24+00:00 https://thepharmadata.com/wp-content/uploads/2024/02/AbbVie-and-Tentarix-Partner-to-Innovate-Conditional-Multi-Specific-Biologics-for-Oncology-and-Immunology-2.webp https://thepharmadata.com/botox-cosmetic-onabotulinumtoxina-unveils-2024-grant-initiative-to-empower-female-entrepreneurs/ 2024-02-24T04:37:29+00:00 https://thepharmadata.com/wp-content/uploads/2024/02/BOTOX%C2%AE-Cosmetic-onabotulinumtoxinA-Unveils-2024-Grant-Initiative-to-Empower-Female-Entrepreneurs.webp https://thepharmadata.com/understanding-heart-failure-its-likely-not-what-you-imagine/ 2024-02-24T04:31:37+00:00 https://thepharmadata.com/wp-content/uploads/2024/02/Understanding-Heart-Failure-Its-Likely-Not-What-You-Imagine.webp https://thepharmadata.com/kalvista-pharmaceuticals-awarded-uk-innovation-passport-for-sebetralstat/ 2024-02-20T11:57:39+00:00 https://thepharmadata.com/wp-content/uploads/2024/02/Pharmaceuticals.webp https://thepharmadata.com/argenxs-vyvgart-hytrulo-receives-fda-priority-review-for-chronic-inflammatory-demyelinating-polyneuropathy/ 2024-02-20T11:52:36+00:00 https://thepharmadata.com/wp-content/uploads/2024/02/Chronic-Inflammatory.jpg https://thepharmadata.com/diakonos-oncology-appoints-veteran-biopharma-senior-executive-dr-paul-lammers-to-board-of-directors/ 2024-02-20T11:43:19+00:00 https://thepharmadata.com/wp-content/uploads/2024/02/Diakonos-Oncology-Appoints-Veteran-BioPharma-Senior-Executive-Dr.-Paul-Lammers-to-Board-of-Directors.webp https://thepharmadata.com/health-canada-grants-approval-for-remsima-sc-in-treating-inflammatory-bowel-disease-ibd/ 2024-02-20T11:40:22+00:00 https://thepharmadata.com/wp-content/uploads/2024/02/Health-Canada-Grants-Approval-for-Remsima%E2%84%A2-SC-in-Treating-Inflammatory-Bowel-Disease.webp https://thepharmadata.com/mrm-health-initiates-clinical-research-in-parkinsons-disease/ 2024-02-20T11:36:53+00:00 https://thepharmadata.com/wp-content/uploads/2024/02/MRM-Health-Initiates-Clinical-Research-in-Parkinsons-Disease.webp https://thepharmadata.com/abbvie-reveals-latest-gastroenterology-data-at-ecco-congress/ 2024-02-20T11:28:53+00:00 https://thepharmadata.com/wp-content/uploads/2024/02/AbbVie-Reveals-Latest-Gastroenterology-Data-at-ECCO-Congress.webp https://thepharmadata.com/lupin-granted-u-s-fda-approval-for-minzoya-levonorgestrel-and-ethinyl-estradiol-tablets-usp-and-ferrous-bisglycinate-tablets/ 2024-02-17T06:54:47+00:00 https://thepharmadata.com/wp-content/uploads/2024/02/Lupin-Granted-U.S.webp https://thepharmadata.com/effrx-pharmaceuticals-enters-exclusive-licensing-and-distribution-partnership-with-lupin-for-binosto-commercialization-in-vietnam-philippines/ 2024-02-17T05:59:01+00:00 https://thepharmadata.com/wp-content/uploads/2024/02/EffRx-Pharmaceuticals-Enters-Exclusive-Licensing-and-Distribution-Partnership-with-Lupin-for-BINOSTO.webp